1. Endometrial cancer diagnosed after hysterectomy There are many problems in the management of endometrial cancer diagnosed only after hysterectomy alone, especially in those with unresected adnexa. This most often occurs in patients who have undergone transvaginal total hysterectomy because of pelvic organ prolapse. Further postoperative treatment should be recommended according to the high-risk factors associated with causing extrauterine spread, such as tissue grade and depth of myofibular infiltration. grade G3, deep myofibular infiltration, and lymphatic vascular involvement (LVSI) should be treated with reoperative adnexal resection and completion of surgical staging, or adjuvant external pelvic irradiation. grade G1 or G2, superficial myofibular infiltration, and no lymphatic vascular involvement generally do not require further treatment. 2.Patients who cannot receive surgical treatment Morbid obesity and severe cardiopulmonary disease are common contraindications to surgery for patients with endometrial cancer. Intracavitary brachytherapy can achieve a cure rate of more than 70%, and can be combined with external pelvic irradiation in the presence of high-risk factors such as lymph node involvement. Radiotherapy provides better control of stage I and II endometrial cancer with a recurrence rate of less than 16%. For those with good differentiation, contraindication to general anesthesia and inappropriate for radiotherapy, high-dose progestin therapy can be used. 3.Diagnosis of endometrial cancer in young women Diagnosis of endometrial cancer in women of reproductive age should be cautious because endometrial cancer under 35 years old is rare and G1 grade endometrial cancer is easily confused with severe endometrial atypical hyperplasia. Attention should be paid to the presence of undetected estrogen-related disorders such as granulosa cell tumors, polycystic ovaries, or obesity. If preservation of fertility is desired, treatment with progestins such as megestrol acetate 160 mg/d or medroxyprogesterone acetate 500 mg/d is indicated. Several large studies have shown that progestin therapy is safe for G1 endometrioid adenocarcinoma and simple atypical hyperplasia. Diagnosis should be made by an experienced pathologist in cases of suspicious lesions. Although successful treatment with preservation of fertility has been reported in the literature, there have been cases of recurrence leading to death after conservative treatment, and removal of the uterus and both adnexa is recommended after completion of fertility tasks. There is data from a large sample of patients with endometrioid adenocarcinoma confined to the endometrium and grade G1 undergoing ovarian preservation surgery with no significant increase in postoperative tumor-related mortality.